SCHEMBL17728870

SCHEMBL17728870

COc1cc(OC)c(Cl)c(N(COCC[Si](C)(C)C)C(=O)N(C)c2cc(Nc3ccc(C4CCN(C(=O)O)C(C(C)(C)C)C4)cc3N)ncn2)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ FGFR1 P11362 18/20 0.44
▸ FGFR3 P22607 5/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ FGFR4 P22455 5/20 0.38
▸ FGFR2 P21802 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17728850 0.87 FGFR1 (0.46) FGFR1FGFR3CYP3A4CYP2C9CYP2C19
SCHEMBL17740814 0.80 FGFR4 (0.49) FGFR1FGFR3FGFR4FGFR2
SCHEMBL16659545 0.79 FGFR1 (0.52) FGFR1FGFR3CYP3A4CYP2C19FGFR4
SCHEMBL18153622 0.79 FGFR1 (0.57) FGFR1FGFR3FGFR4FGFR2
SCHEMBL17740810 0.78 FGFR1 (0.73) FGFR1FGFR3CYP3A4CYP2C9CYP2C19
SCHEMBL17728873 0.77 FGFR1 (0.37) FGFR1FGFR3CYP3A4CYP2C9CYP2C19
SCHEMBL17740757 0.77 FGFR1 (0.38) FGFR1FGFR3FGFR4FGFR2
SCHEMBL17728885 0.76 FGFR1 (0.36) FGFR1FGFR3FGFR4FGFR2
SCHEMBL16654740 0.75 FGFR4 (0.48) FGFR1FGFR3CYP3A4CYP2C9CYP2C19
SCHEMBL22157668 0.75 FGFR1 (0.48) FGFR1FGFR3FGFR4FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3421457-B1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MAN CO LTD (JP) 2021-10-06 — — EP disclosed
US-10912774-B2 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-02-09 — — US disclosed
US-20200206222-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2020-07-02 — — US disclosed
EP-3421457-A1 PYRIMIDINE FGFR4 INHIBITORS Eisai R&D Management Co., Ltd. (JP) 2019-01-02 — — EP disclosed
EP-3057943-B1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MAN CO LTD (JP) 2018-04-25 — — EP disclosed
US-20170360785-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-12-21 — — US disclosed
US-9730931-B2 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-08-15 — — US disclosed
US-20170007601-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-01-12 — — US disclosed
US-9434697-B2 Pyrimidine FGFR4 inhibitors EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-09-06 — — US disclosed
US-20160130237-A1 PYRIMIDINE FGFR4 INHIBITORS EISAI R&D MANAGEMENT CO., LTD. (JP) 2016-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360785-A1 PYRIMIDINE FGFR4 INHIBITORS FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR3 3/4885CYP3A4 929/4885
US-10912774-B2 Pyrimidine FGFR4 inhibitors FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR3 3/4885CYP3A4 929/4885
US-20160130237-A1 PYRIMIDINE FGFR4 INHIBITORS FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR3 3/4885CYP3A4 929/4885
US-20170007601-A1 PYRIMIDINE FGFR4 INHIBITORS FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR3 3/4885CYP3A4 929/4885
US-20200206222-A1 PYRIMIDINE FGFR4 INHIBITORS FGFR4, FGFR1, FGFR3 FGFR1 2/4885FGFR3 3/4885CYP3A4 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback